<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>health economics</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>health economics | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Cost-effective boosting allocations in the post-Omicron era of COVID-19 management
Authors: Le, T. P.; Conway, E.; Akpan, E.; Abell, I.; Abraham, P.; Baker, C. M.; Campbell, P. T.; Cromer, D.; Lydeamore, M. J.; McDonough, Y.; Mueller, I.; Ryan, G.; Walker, C.; Wang, Y.; Carvalho, N.; McVernon, J.
Score: 2.2, Published: 2023-11-15 DOI: 10.1101/2023.11.14.23298536
BackgroundFollowing widespread exposure to Omicron variants, COVID-19 has transitioned to endemic circulation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous immune landscapes.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/health-economics/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="health economics" />
<meta property="og:description" content="Cost-effective boosting allocations in the post-Omicron era of COVID-19 management
Authors: Le, T. P.; Conway, E.; Akpan, E.; Abell, I.; Abraham, P.; Baker, C. M.; Campbell, P. T.; Cromer, D.; Lydeamore, M. J.; McDonough, Y.; Mueller, I.; Ryan, G.; Walker, C.; Wang, Y.; Carvalho, N.; McVernon, J.
Score: 2.2, Published: 2023-11-15 DOI: 10.1101/2023.11.14.23298536
BackgroundFollowing widespread exposure to Omicron variants, COVID-19 has transitioned to endemic circulation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous immune landscapes." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/health-economics/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-11-29T10:40:14+00:00" />
<meta property="article:modified_time" content="2023-11-29T10:40:14+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="health economics"/>
<meta name="twitter:description" content="Cost-effective boosting allocations in the post-Omicron era of COVID-19 management
Authors: Le, T. P.; Conway, E.; Akpan, E.; Abell, I.; Abraham, P.; Baker, C. M.; Campbell, P. T.; Cromer, D.; Lydeamore, M. J.; McDonough, Y.; Mueller, I.; Ryan, G.; Walker, C.; Wang, Y.; Carvalho, N.; McVernon, J.
Score: 2.2, Published: 2023-11-15 DOI: 10.1101/2023.11.14.23298536
BackgroundFollowing widespread exposure to Omicron variants, COVID-19 has transitioned to endemic circulation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous immune landscapes."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "health economics",
      "item": "https://trxiv.yorks0n.com/posts/health-economics/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "health economics",
  "name": "health economics",
  "description": "Cost-effective boosting allocations in the post-Omicron era of COVID-19 management\nAuthors: Le, T. P.; Conway, E.; Akpan, E.; Abell, I.; Abraham, P.; Baker, C. M.; Campbell, P. T.; Cromer, D.; Lydeamore, M. J.; McDonough, Y.; Mueller, I.; Ryan, G.; Walker, C.; Wang, Y.; Carvalho, N.; McVernon, J.\nScore: 2.2, Published: 2023-11-15 DOI: 10.1101/2023.11.14.23298536\nBackgroundFollowing widespread exposure to Omicron variants, COVID-19 has transitioned to endemic circulation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous immune landscapes.",
  "keywords": [
    
  ],
  "articleBody": " Cost-effective boosting allocations in the post-Omicron era of COVID-19 management\nAuthors: Le, T. P.; Conway, E.; Akpan, E.; Abell, I.; Abraham, P.; Baker, C. M.; Campbell, P. T.; Cromer, D.; Lydeamore, M. J.; McDonough, Y.; Mueller, I.; Ryan, G.; Walker, C.; Wang, Y.; Carvalho, N.; McVernon, J.\nScore: 2.2, Published: 2023-11-15 DOI: 10.1101/2023.11.14.23298536\nBackgroundFollowing widespread exposure to Omicron variants, COVID-19 has transitioned to endemic circulation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous immune landscapes. Careful consideration of vaccination is required through the post-Omicron phase of COVID-19 management to minimise disease burden. We assess the impact and cost-effectiveness of targeted COVID-19 vaccination strategies to support global vaccination recommendations. MethodsWe integrated immunological, transmission, clinical and cost-effectiveness models, and simulated populations with different characteristics and immune landscapes. We calculated the expected number of infections, hospitalisations and deaths for different vaccine scenarios. Costs (from a healthcare perspective) were estimated for exemplar country income level groupings in the Western Pacific Region. Results are reported as incremental costs and disability-adjusted life years averted compared to no additional vaccination. Parameter and stochastic uncertainty were captured through scenario and sensitivity analysis. FindingsAcross different population demographics and income levels, we consistently found that annual elder-targeted boosting strategies are most likely to be cost-effective or cost-saving, while paediatric programs are unlikely to be cost-effective. Results remained consistent while accounting for uncertainties in the epidemiological and economic models. Half-yearly boosting may only be cost-effective in higher income settings with older population demographics and higher cost-effectiveness thresholds. InterpretationThe seresults demonstrate the value of continued booster vaccinations to protect against severe COVID-19 disease outcomes across high and middle-income settings and show that the biggest health gains relative to vaccine costs are achieved by targeting older age-groups. FundingFunded by the World Health Organization. O_TEXTBOXResearch in context Evidence before this studyWith COVID-19 now globally endemic, populations exhibit varying levels of natural and vaccine-acquired immunity to SARS-CoV-2. With widespread, if variable, immunity resulting in reduced severity of COVID-19 disease, re-evaluation of the ongoing value of vaccination is required. COVID-19 vaccination strategies must consider the cost-effectiveness of gains from vaccination given prior immunity, and in the context of income and health system capacity to manage COVID-19 alongside other pressing concerns. Few articles examine cost-effectiveness of COVID-19 vaccination strategies in populations with diverse characteristics and waning hybrid immunity, though there is a large body of literature that considers some combination of these elements or focus on one particular country. Consensus is that allocating vaccine doses to older age groups and those at higher risk of severe disease is most beneficial, albeit assuming either only past natural immunity or no waning immunity. These studies have either not included a cost-effectiveness analysis or, where present, have typically assumed a base case zero-vaccination scenario. Added value of this studyWe consider the contemporary situation where populations have varying degrees of hybrid immunity resulting from both prior infection and vaccination, and where the relevant cost-effectiveness analysis considers only future primary and booster doses in the population. We describe multiple demographics, using exemplar older and younger populations, in conjunction with low to high past vaccination coverage, low to high past natural infection incidence, and low to high income levels. Under these settings, we determine the cost-effectiveness of a range of targeted boosting strategies (who, when, what). Implications of all the available evidenceOur study highlights how future COVID-19 booster doses targeted towards older age groups at risk of severe outcomes can be cost-effective or cost-saving in high-income settings with populations that have a higher proportion of individuals at risk. In younger, lower-resourced settings, annual boosting of older age groups may still be cost-effective or cost-saving in some scenarios. We consistently find that pediatric vaccination is not cost-effective. Given the benefits of vaccination, especially to reduce severe disease, we show the importance of ongoing global efforts to provide and equitably distribute vaccines and strengthen adult immunisation programs. C_TEXTBOX\n",
  "wordCount" : "646",
  "inLanguage": "en",
  "datePublished": "2023-11-29T10:40:14Z",
  "dateModified": "2023-11-29T10:40:14Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/health-economics/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      health economics
    </h1>
    <div class="post-meta">&lt;span&gt;updated on November 29, 2023&lt;/span&gt;

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.11.14.23298536">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.11.14.23298536" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.11.14.23298536">
        <p class="paperTitle">Cost-effective boosting allocations in the post-Omicron era of COVID-19 management</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.11.14.23298536" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.11.14.23298536" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Le, T. P.; Conway, E.; Akpan, E.; Abell, I.; Abraham, P.; Baker, C. M.; Campbell, P. T.; Cromer, D.; Lydeamore, M. J.; McDonough, Y.; Mueller, I.; Ryan, G.; Walker, C.; Wang, Y.; Carvalho, N.; McVernon, J.</p>
        <p class="info">Score: 2.2, Published: 2023-11-15 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.11.14.23298536' target='https://doi.org/10.1101/2023.11.14.23298536'> 10.1101/2023.11.14.23298536</a></p>
        <p class="abstract">BackgroundFollowing widespread exposure to Omicron variants, COVID-19 has transitioned to endemic circulation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous immune landscapes. Careful consideration of vaccination is required through the post-Omicron phase of COVID-19 management to minimise disease burden. We assess the impact and cost-effectiveness of targeted COVID-19 vaccination strategies to support global vaccination recommendations.

MethodsWe integrated immunological, transmission, clinical and cost-effectiveness models, and simulated populations with different characteristics and immune landscapes. We calculated the expected number of infections, hospitalisations and deaths for different vaccine scenarios. Costs (from a healthcare perspective) were estimated for exemplar country income level groupings in the Western Pacific Region. Results are reported as incremental costs and disability-adjusted life years averted compared to no additional vaccination. Parameter and stochastic uncertainty were captured through scenario and sensitivity analysis.

FindingsAcross different population demographics and income levels, we consistently found that annual elder-targeted boosting strategies are most likely to be cost-effective or cost-saving, while paediatric programs are unlikely to be cost-effective. Results remained consistent while accounting for uncertainties in the epidemiological and economic models. Half-yearly boosting may only be cost-effective in higher income settings with older population demographics and higher cost-effectiveness thresholds.

InterpretationThe seresults demonstrate the value of continued booster vaccinations to protect against severe COVID-19 disease outcomes across high and middle-income settings and show that the biggest health gains relative to vaccine costs are achieved by targeting older age-groups.

FundingFunded by the World Health Organization.

O_TEXTBOXResearch in context

Evidence before this studyWith COVID-19 now globally endemic, populations exhibit varying levels of natural and vaccine-acquired immunity to SARS-CoV-2. With widespread, if variable, immunity resulting in reduced severity of COVID-19 disease, re-evaluation of the ongoing value of vaccination is required. COVID-19 vaccination strategies must consider the cost-effectiveness of gains from vaccination given prior immunity, and in the context of income and health system capacity to manage COVID-19 alongside other pressing concerns.

Few articles examine cost-effectiveness of COVID-19 vaccination strategies in populations with diverse characteristics and waning hybrid immunity, though there is a large body of literature that considers some combination of these elements or focus on one particular country. Consensus is that allocating vaccine doses to older age groups and those at higher risk of severe disease is most beneficial, albeit assuming either only past natural immunity or no waning immunity. These studies have either not included a cost-effectiveness analysis or, where present, have typically assumed a base case zero-vaccination scenario.

Added value of this studyWe consider the contemporary situation where populations have varying degrees of hybrid immunity resulting from both prior infection and vaccination, and where the relevant cost-effectiveness analysis considers only future primary and booster doses in the population. We describe multiple demographics, using exemplar  older and  younger populations, in conjunction with low to high past vaccination coverage, low to high past natural infection incidence, and low to high income levels. Under these settings, we determine the cost-effectiveness of a range of targeted boosting strategies (who, when, what).

Implications of all the available evidenceOur study highlights how future COVID-19 booster doses targeted towards older age groups at risk of severe outcomes can be cost-effective or cost-saving in high-income settings with populations that have a higher proportion of individuals at risk. In younger, lower-resourced settings, annual boosting of older age groups may still be cost-effective or cost-saving in some scenarios. We consistently find that pediatric vaccination is not cost-effective. Given the benefits of vaccination, especially to reduce severe disease, we show the importance of ongoing global efforts to provide and equitably distribute vaccines and strengthen adult immunisation programs.

C_TEXTBOX</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
